Milestone received $13 million in equity financing

Guest Contributor
June 22, 2011

Montreal's Milestone Pharmaceuticals Inc has completed a $13-million equity financing to further development of its flagship compound (MSP-2017) for the treatment of a cardiac arrhythmia called paroxysmal supraventricular tachycardia (PSVT). The financing was provided by Pappas Ventures, the BDC Health Venture Fund, GO Capital, Fonds de solidarite FTQ, and previous investors iNovia Healthcare and Fonds Bio-Innovation. The preclinical company hopes MSO-2917 will become an effective "pill-in-the-pocket" to terminate acute PSVT episodes without having to resort to the emergency room, thereby driving down health care costs....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.